Comparison of serological specificity of anti-endotoxin sera directed against whole bacterial cells and core oligosaccharide of Escherichia coli J5-tetanus toxoid conjugate

• Autorzy: Lukasiewicz J. , Jachymek W. , Niedziela T. , Malik-Gebicka M. , Dzieciatkowska M. , Lugowski C.
• Języki publikacji: EN

Abstrakty

EN

The rough mutants of Gram-negative bacteria are widely used to induce protective antisera but the nature of the target epitope for such antibodies is not precisely de­fined. Endotoxin is one of several antigens present on the surface of bacterial cells, which are able to elicit specific antibodies. We studied the specificity of antibodies produced against a conjugate of E. coli J5 endotoxin core oligosaccharide with tetanus toxoid. The use of chemically defined antigen for immunisation excludes the possibil­ity of production of antibodies against other cell surface antigens. A comparison of this monospecific anti-endotoxin serum with antiserum against E. coli J5 whole cells was performed in order to distinguish the role that endotoxin core oligosaccharide plays in the interaction with humoral host defences from that of other potentially im­portant Gram-negative bacterial surface antigens. The reactivity of both sera with smooth and rough lipopolysaccharides was determined in ELISA, immunoblotting and by flow cytometry. Both antisera reacted with similar specificity with most lipopolysaccharides of identical or related core type. Less distinct reactions with endotoxins of the antibacterial serum in comparison with the anti-conjugate serum were found in all serological tests. LPS of E. coli O100 that showed the strongest reactions with both sera was used to stimulate IL-6, TNFα and nitric oxide production by the J-774A.1 cell line. Both sera were used to inhibit that stimulation and no inhibitory effects of the examined sera in comparison with non-immune serum were observed.

Słowa kluczowe

EN

anti-endotoxin serum; Gram-negative bacterium; lipopolysaccharide; ELISA test; oligosaccharide; Escherichia coli; bacterial cell; mutant; serological specificity; core region; antibody; endotoxin

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2002
• Tom: 49
• Numer: 3
• Opis fizyczny: p.721-734,fig.

Twórcy

autor

Lukasiewicz J.

• Polish Academy of Sciences, R.Weigla 12, 53-114 Wroclaw, Poland

autor

Jachymek W.

autor

Niedziela T.

autor

Malik-Gebicka M.

autor

Dzieciatkowska M.

autor

Lugowski C.

Bibliografia

• Appelmelk BJ, Rapson NT, Verweij-van Vught AM, Maaskant JJ, Hekker TA, Peerbooms PG, MacLaren DM, Thijs LG. (1986) Heterogeneity of Escherichia coli J5 vaccines. Lancet.; 2: 1273-4.
• Appelmelk BJ, Maaskant JJ, Verweij-van Vught AM, Van der Meer NM, Thijs BG, MacLaren DM. (1993) Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins. J Gen Microbiol.; 139: 2641-7.
• Bhattacharjee AK, Opal SM, Palardy JE, Drabick JJ, Collins H, Taylor R, Cotton A, Cross AS. (1994) Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against Gram-negative bacterial sepsis. J Infect Dis.; 170: 622-9.
• Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS. (1996) A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against Gram-negative bacteremia. J Infect Dis.; 173: 1157-63.
• Brauner A, Kallenius G, Wrangsell G, Wretlind B, Svenson SB. (1986) Antibody responses to Escherichia coli J5 lipopolysaccharide and to Salmonella porin in patients with bacteremia. Microb Pathog.; 1: 475-81.
• Cross AS, Opal SM, Warren HS, Palardy JE, Glaser K, Parejo NA, Bhattacharjee AK. (2001) Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis.; 183: 1079-86.
• Dunn DL, Ferguson RM. (1982) Immunotherapy of Gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery.; 92: 212-9.
• Elbein AD, Heath EC. (1965) The biosynthesis of cell wall lipopolysaccharide in Escherichia coli. I. The biochemical properties of a uridine diphosphate galactose 4-epimeraseless mutant. J Biol Chem.; 240: 1919-25.
• Espevik T, Nissen-Meyer J. (1986) A higly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods.; 95: 99-105.
• Evans ME, Pollack M, Koles NL, Hardegen NJ, Panopoulos D. (1992) Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. J Infect Dis.; 166: 803-11.
• Galanos C, Luderitz O, Westphal O. (1969) A new method for the extraction of R lipopolysaccharides. Eur J Biochem.; 9: 245-9.
• Hakomori S. (1964) A rapid permethylation of glycolipid and polysaccharide catalyzed by methylsulphinyl carbanion in dimethyl sulphoxide. J Biochem. ; 55: 205-8.
• Hansen BM, Nielsen SE, Berg K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods.; 119: 203-10.
• Hellman J, Warren HS. (1999) Antibodies against bacterial membrane proteins. J Endotoxin Res.; 5: 213-5.
• Hellman J, Zanzot EM, Loiselle PM, Amato SF, Black KM, Ge YM, Kurnick JT, Warren HS. (1997) Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous Gram-negative bacteria. J Infect Dis.; 176: 1260-8.
• Hellman J, Loiselle PM, Zanzot EM, Allaire JE, Tehan MM, Boyle LA, Kurnick JT, Warren HS. (2000) Release of Gram­negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5. J Infect Dis.; 181: 1034-43.
• Hogan JS, Bogacz VL, Aslam M, Smith KL. (1999) Efficacy of an Escherichia coli J5 bacterin administered to primigravid heifers. J Dairy Sci.; 82: 939-43.
• Holst O, Ulmer AJ, Brade H, Flad H, Rietschel E. (1996) Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol. ; 16: 83-104.
• Hustinx WNM, Kraaijeveld K, Hoepelman AIM, Verhoef J. (1997) Cross-protection by anti-core glycolipid antibodies: evidence from animal experiments. JAntimicrob Chemother.; 40: 475-83.
• Jennings HJ, Lugowski C. (1982) Tetanus toxoid conjugates of the meningococcal polysaccharides. Bact Vaccines.; 4: 247-53.
• Kabat EA, Mayer MM. (1967) Precipitin reaction. In Experimental Immunochemistry. pp 22-96. Charles C Thomas, Springfield.
• Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature.; 227: 680-5.
• Li JJ, Bauer SHJ, Mansson M, Moxon ER, Richards JC, Schweda EKH. (2001) Glycine is a common substituent of the inner core in Haemophilus influenzae lipopolysaccharide. Glycobiology.; 11: 1009-15.
• Lugowski C, Romanowska E. (1978) Enterobacterial common antigen: isolation from Shigella sonnei, purification and immunochemical characterization. Eur J Biochem.; 91: 89-97.
• Lugowski C, Jachymek W, Niedziela T, Rowinski S. (1996a) Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid. FEMS Immunol Med Microbiol. ; 16: 21-30.
• Lugowski C, Niedziela T, Jachymek W. (1996b) Anti-endotoxin antibodies directed against Escherichia coli R-1 oligosaccharide core-tetanus toxoid conjugate bind to smooth, live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity. FEMS Immunol Med Microbiol.; 16: 31-8.
• Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods.; 65: 55-63.
• Muller-Loennies S, Holst O, Brade H. (1994) Chemical structure of the core region of Escherichia coli J-5 lipopolysaccharide. Eur J Biochem.; 224, 751-60.
• Muller-Loennies S, Holst O, Lindner B, Brade H. (1999) Isolation and structural analysis of phosphorylated oligosaccharides obtained from Escherichia coli J-5 lipopolysaccharide. Eur J Biochem.; 260: 235-49.
• Niedziela T, Petersson C, Helander A, Jachymek W, Kenne L, Lugowski C. (1996) Structural studies of the O-specific polysaccharide of Hafnia alvei strain 1209 lipopolysaccharide. Eur J Biochem.; 237: 635-41.
• Niedziela T, Lukasiewicz J, Jachymek W, Dzieciatkowska M, Lugowski C, Kenne L. (2002) Core oligosaccharides of Plesiomonas shigelloides O54:H2 (strain CNCTC 113/92). Structural and serological analysis of the lipopolysaccharide core region, the O-antigen biological repeating unit, and the linkage between them. J Biol Chem.; 277: 11653-63.
• Petersson C, Niedziela T, Jachymek W, Kenne L, Zarzecki P, Ługowski C. (1997) Structural studies of the O-specific polysaccharide of Hafnia alvei strain PCM 1206 lipopolysaccharide containing D-allothreonine. Eur J Biochem.; 244: 580-6.
• Romanowska A, Katzenellenbogen E, Kulakowska M, Gamian A, Witkowska D, Mulczyk M, Romanowska E. (1988) Hafnia alvei lipopolysaccharides: isolation, sugar composition and SDS/PAGE analysis. FEMS Microbiol Immunol.; 1: 151-5.
• Sakulramrung R, Domingue GJ. (1985) Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5. J Infect Dis.; 151: 995-1004.
• Schmidt HHW. (1995) Determination of nitric oxide via measurement of nitrite and nitrate in culture media. Biochemica.; 2: 22.
• Tsai CM, Frasch CE. (1982) A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem.; 119: 115-9.
• Voller A, Draper C, Bidwell DE, Bartlett A. (1975) Microplate enzyme-linked immunosorbent assay for Chagas' disease. Lancet.; 1: 426-8.
• Ziegler EJ, Douglas H, Sherman JE, Davis CE, Braude AI. (1973) Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol.; Ill: 433-8.